Clinical Trials

Several clinical trials evaluate the therapeutic applications and pharmacokinetic parameters of this compound in conditions including diabetic foot, metastatic melanoma, and BRAF-mutated metastatic melanoma. Sponsored by institutions such as Hacettepe University, Novartis Pharmaceuticals, and Scynexis Inc., these Phase I, unassigned, and non-applicable phase studies encompass recruiting, completed, and terminated recruitment statuses.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05974592 Recruiting
Diabetic Foot
Hacettepe University
 2023-09-01 Not Applicable
NCT06251934 Completed
BRAF-positive Metastatic Melanoma
Novartis Pharmaceuticals|Novartis
 2022-09-28 --
NCT05848219 Terminated
Metastatic Melanoma
Novartis Pharmaceuticals|Novartis
 2021-10-16 --
NCT05806268 Completed
BRAF v600 Mutated Metastatic Melanoma
Novartis Pharmaceuticals|Novartis
 2021-07-30 --
NCT04092725 Completed
Pharmacokinetics
Scynexis Inc.|Clinical Network Services (CNS) Pty Ltd
 2019-09-09 Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 3,3'-Diaminobenzidine tetrahydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

3,3'-Diaminobenzidine tetrahydrochloride acts as an electron-donating chromogenic substrate that undergoes horseradish peroxidase-catalyzed oxidation in the presence of hydrogen peroxide, generating an insoluble brown polymeric precipitate. This site-specific precipitation enables precise visualization of targeted proteins or nucleic acids, supporting diagnostic and immunohistochemical assessments relevant to clinical conditions such as metastatic melanoma and diabetic foot care.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.